Skip to content

Author

M. Haendel

We have 5 of 434 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Increasing Multimorbidity Burden After COVID-19 Infection Among People With and Without HIV in the United States: Insights From the National Clinical Cohort Collaborative (N3C)

Abstract Background People with HIV (PWH) have a disproportionately high burden of chronic comorbidities. However, how their multimorbidity patterns differ from those of the general population and how COVID-19 infection may affect this burden have not been well characterized. Methods We conducted a retrospective cohort...

Yu-Meng Wang, Ahmed Sabit, J. Anzalone et al. · 0 citations
Review Open access Aug 2026

The Gabriella Miller Kids First Data Resource for genomic research in pediatric cancer and congenital anomalies.

Nine-year-old brain tumor patient Gabriella Miller challenged members of Congress to "stop talking and start doing" when providing federal funding for research into cures for pediatric cancer and congenital anomalies. Though she ultimately lost her life to that cancer, her advocacy efforts resulted in the 2014 Gabriell...

David M Higgins, Christopher Blackden, Miguel A. Brown et al. · 0 citations
Open access Aug 2026

Every Cure Knowledge Graph: A Unified Biomedical Knowledge Graph for Drug Repurposing

EC-KG is an interoperable, provenance-first KG which integrates RTX-KG2, ROBOKOP, and PrimeKG at the network-level, encapsulating over 7 million nodes and 81 million edges from 95 primary data sources, and has improved coverage of core biomedical entities, and captures complex biomedical mechanisms within its topology.

Piotr Kaniewski, E. K. Carter, Daniel J. Rhodes et al. · 0 citations
Open access Aug 2026

Real-world effectiveness of early nirmatrelvir/ritonavir initiation after COVID-19 diagnosis in outpatient setting against severe illness, hospitalization, death, and long COVID in N3C

Evaluated the real-world effectiveness of NMV-R in preventing severe illness, hospitalization, death and long-COVID in a large nationwide cohort of outpatients with COVID-19 and found it overall effective at preventing the risk of severe acute outcomes including hospitalization and death, as well as long COVID.

Steve R Makkar, Kristen Hansen, Arjun S. Yadaw et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.